<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01502072</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0813</org_study_id>
    <secondary_id>NCI-2012-00021</secondary_id>
    <nct_id>NCT01502072</nct_id>
  </id_info>
  <brief_title>Respiratory Syncytial Virus - RSV Protocol</brief_title>
  <official_title>An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if ribavirin can help to control RSV in&#xD;
      patients with immune systems that have been weakened by a stem cell transplant. Researchers&#xD;
      also want to compare the effectiveness of the drug when it is given by mouth to when it is&#xD;
      inhaled. The safety of the drug in both methods of delivery will be studied.&#xD;
&#xD;
      Ribavirin is designed to prevent the RSV virus from making more copies of itself in the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study and the study doctor thinks that&#xD;
      the disease requires treatment at this time, you will be randomly assigned (as in the flip of&#xD;
      a coin) to 1 of 2 study groups. You will have an equal chance of being assigned to either&#xD;
      group:&#xD;
&#xD;
        -  If you are in Group 1, you will receive the inhaled form of ribavirin. You will inhale&#xD;
           ribavirin 3 times a day for 3 hours each time in a tent in a hospital room. You will&#xD;
           receive the drug for up to 10 days.&#xD;
&#xD;
        -  If you are in Group 2, you will take capsules of ribavirin 3 times a day for up to 10&#xD;
           days.&#xD;
&#xD;
      If the study doctor does not think that the disease requires treatment at this time, you will&#xD;
      be assigned to Group 3. If you are in Group 3, you will not receive treatment with ribavirin,&#xD;
      but you will have the same tests and procedures at the study visits described below.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      At all study visits, you will be asked about how you are feeling, about any side effects or&#xD;
      symptoms you may be having, and about any other drugs you may be taking.&#xD;
&#xD;
      On Day 3 (+/- 1 day):&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs&#xD;
&#xD;
        -  Your nasal passages will be checked for RSV.&#xD;
&#xD;
      On Days 7 and 14 (+/- 1 day):&#xD;
&#xD;
        -  Blood (about 2 teaspoons) will be drawn for routine tests.&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs&#xD;
&#xD;
        -  Your nasal passages will be checked for RSV.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      If you are in Groups 1 or 2, you will receive the study drug for up to 10 days. You will no&#xD;
      longer be able to take the study drug if the disease gets worse, if intolerable side effects&#xD;
      occur, or if you are unable to follow study directions. If your doctor thinks you need&#xD;
      treatment longer than 10 days, you will receive that as part of your routine care. This may&#xD;
      mean changing to receiving the drug in inhaled form if you began the study receiving it by&#xD;
      mouth.&#xD;
&#xD;
      All participants will have end-of-study and follow-up visits, as described below.&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      If you are in Groups 1 or 2, the end-of-study visit will be about 14 days after your last&#xD;
      dose of the study drug. If you are in Group 3, the end-of-study visit will take place at&#xD;
      about Day 21. The following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs.&#xD;
&#xD;
        -  Blood (about 4 teaspoons) will be drawn for routine tests and to check for RSV&#xD;
           antibodies.&#xD;
&#xD;
        -  Your nasal passages will be checked for RSV.&#xD;
&#xD;
        -  You will be asked about how you are feeling, about any side effects or symptoms you may&#xD;
           be having, and about any drugs you may be taking.&#xD;
&#xD;
      Follow-Up Visit:&#xD;
&#xD;
      About 6 to 10 weeks after your last dose of study drug, you will have a pulmonary function&#xD;
      test to check your lung function.&#xD;
&#xD;
      This is an investigational study. Ribavirin is FDA approved and commercially available for&#xD;
      the treatment of hepatitis C when given by mouth, and for severe RSV in children when&#xD;
      inhaled. Giving the drug to adults with weak immune systems after a stem cell transplant is&#xD;
      investigational.&#xD;
&#xD;
      Up to 96 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 28, 2011</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI)</measure>
    <time_frame>14 days</time_frame>
    <description>Patient who developed signs of lower respiratory tract infection</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Bone Marrow Transplant Infection</condition>
  <condition>Infection in Marrow Transplant Recipients</condition>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <condition>Respiratory Syncytial Virus Pneumonia</condition>
  <condition>Cancer</condition>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>Inhaled Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Ribavirin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group 3: No Ribavirin treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.</description>
    <arm_group_label>Inhaled Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).</description>
    <arm_group_label>Oral Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HSCT patients with either moderate or severe immunodeficiency based on&#xD;
             immunodeficiency scoring system would be eligible for entry on study if a&#xD;
             nasopharyngeal wash or throat swab specimen is positive by rapid RSV antigen testing&#xD;
             and/or on culture within 72 hours (therapeutic arms). (Please see Appendix E for&#xD;
             definitions and Immunodeficiency Scoring).&#xD;
&#xD;
          2. HSCT patients with mild immunodeficiency based on immunodeficiency scoring system&#xD;
             would be eligible for entry on study if a nasopharyngeal wash or throat swab specimen&#xD;
             is positive by rapid RSV antigen testing and/or on culture within 72 hours but will&#xD;
             not be randomized to therapeutic arms and will be followed as per standard of care&#xD;
             (control arm).&#xD;
&#xD;
          3. Patients must be at least 18 years of age and able to swallow pills.&#xD;
&#xD;
          4. Patients with RSV infection limited to the URT as documented by negative Chest&#xD;
             radiographic findings within the last 48 hours of enrollment and pulse oxygenation of&#xD;
             more than 90 mm of Hg on room air.&#xD;
&#xD;
          5. Women of child bearing potential with a negative urine or blood pregnancy test within&#xD;
             a month of enrollment (only for patients who are going to be randomised to either&#xD;
             therapeutic arms).&#xD;
&#xD;
          6. Patients with Hemoglobin levels more than or equal to 8 g/dl would be eligible for the&#xD;
             study even if they are currently receiving blood products.&#xD;
&#xD;
          7. Patients may receive up to 2 doses of aerosolized ribavirin (modified regimen) before&#xD;
             enrollment into the study.&#xD;
&#xD;
          8. Patients who will be enrolled on the observational arm should meet inclusion criteria&#xD;
             # 2, 3, and 4 only.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with previous history of hypersensitivity to ribavirin or its components&#xD;
&#xD;
          2. Women who are pregnant or plan a pregnancy within 8 weeks after completion of&#xD;
             treatment (only for patients who are going to be randomised to either therapeutic&#xD;
             arms).&#xD;
&#xD;
          3. Patients with evidence of RSV LRI as documented by a positive rapid RSV antigen&#xD;
             testing and/or culture on nasal washes AND new or progressive infiltrates on chest&#xD;
             radiographic studies suggestive of viral etiology and/or pulse oxygen less than 90 mm&#xD;
             of Hg on room air.&#xD;
&#xD;
          4. Patients with positive RSV by rapid antigen testing and/or culture in bronchoalveolar&#xD;
             lavage regardless of the chest radiographic findings.&#xD;
&#xD;
          5. Patients who are considered to be moderately or severely anemic as per the NCI&#xD;
             classification will not be included in the study, i.e patients with hemoglobin level&#xD;
             less than 8 g/dl&#xD;
&#xD;
          6. Patient with Total Bilirubin and Aspartate Aminotransferase (AST) or Alanine&#xD;
             Aminotransferase (ALT) three times the upper limit of normal.&#xD;
&#xD;
          7. Male partners of women who are pregnant (only for patients who are going to be&#xD;
             randomised to either therapeutic arms).&#xD;
&#xD;
          8. Patients with known history of autoimmune hepatitis, Hepatitic C or those with&#xD;
             hemoglobinopathies (eg, thalassemia major, sickle cell anemia).&#xD;
&#xD;
          9. Patients with creatinine clearance of less than or equal to 50 ml/Min&#xD;
&#xD;
         10. Patients taking didanosine, azathioprine, or nucleoside reverse transcriptase&#xD;
             inhibitors&#xD;
&#xD;
         11. Patients who will be enrolled on the observational arm should not meet exclusion&#xD;
             criteria #3 and 4 only.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy F. Chemaly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2011</study_first_posted>
  <results_first_submitted>January 21, 2021</results_first_submitted>
  <results_first_submitted_qc>January 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2021</results_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ribavirin</keyword>
  <keyword>Ribavirin Aerosol</keyword>
  <keyword>Respiratory Syncytial Virus</keyword>
  <keyword>RSV</keyword>
  <keyword>upper respiratory tract infection</keyword>
  <keyword>URI</keyword>
  <keyword>Lower respiratory tract Infection</keyword>
  <keyword>LRI</keyword>
  <keyword>pneumonia</keyword>
  <keyword>aerosolized ribavirin</keyword>
  <keyword>HSCT</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <keyword>oral ribavirin therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 7, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01502072/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: December 2011 - March 2016. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>48 participants enrolled, 4 participants did not meet enrollment criteria after screening labs were performed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Ribavirin</title>
          <description>Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.&#xD;
Ribavirin: One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).</description>
        </group>
        <group group_id="P2">
          <title>Inhaled Ribavirin</title>
          <description>Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.</description>
        </group>
        <group group_id="P3">
          <title>No Ribavirin</title>
          <description>No Ribavirin treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient from the Oral ribavarin group withdrew consent.</population>
      <group_list>
        <group group_id="B1">
          <title>Oral Ribavirin</title>
          <description>Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.</description>
        </group>
        <group group_id="B2">
          <title>Inhaled Ribavirin</title>
          <description>Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.</description>
        </group>
        <group group_id="B3">
          <title>No Ribavirin</title>
          <description>No Ribavirin treatment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="9.9"/>
                    <measurement group_id="B2" value="58.2" spread="12.6"/>
                    <measurement group_id="B3" value="41.5" spread="17.1"/>
                    <measurement group_id="B4" value="50.8" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI)</title>
        <description>Patient who developed signs of lower respiratory tract infection</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Ribavirin</title>
            <description>Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Ribavirin</title>
            <description>Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>No Ribavirin</title>
            <description>No Ribavirin treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI)</title>
          <description>Patient who developed signs of lower respiratory tract infection</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At baseline, up to 2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Ribavirin</title>
          <description>Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.</description>
        </group>
        <group group_id="E2">
          <title>Inhaled Ribavirin</title>
          <description>Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.</description>
        </group>
        <group group_id="E3">
          <title>No Ribavirin</title>
          <description>No Ribavirin treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolar hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening oral ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Clausterphobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Jitteriness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath/hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roy F. Chemaly, MD,MPH- Professor, Infectious Diseases</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 745-1116</phone>
      <email>rfchemaly@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

